<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03326492</url>
  </required_header>
  <id_info>
    <org_study_id>2016-092</org_study_id>
    <nct_id>NCT03326492</nct_id>
  </id_info>
  <brief_title>Evaluation of Anti-venoms Serum in Africa</brief_title>
  <acronym>ESAA</acronym>
  <official_title>Evaluation of Anti-venoms Serum in Africa (ESAA). Data Collection in Real Life Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Pasteur</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cameroon Society of Epidemiology (CaSE)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre International de Recherches d'Enseignements et de Soins (CIRES)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Pasteur du Cameroun</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inosan Biopharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Pasteur</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is little or no assessment under real-use conditions of the efficacy and the tolerance&#xD;
      in the short, medium and long term of the antivenoms currently on the market and used in the&#xD;
      treatment of snake bites.&#xD;
&#xD;
      The main objective is to assess the short term tolerance (&lt; 2 hours post-injection) of the&#xD;
      antivenom Inoserp Pan-Africa® (temporary market authorization) from Inosan laboratory&#xD;
      currently available in Cameroon.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Globally, the number of annual envenomings is estimated to be between 420,000 and 1,800,000.&#xD;
      In sub-Saharan Africa, the annual number of envenomings is estimated at 315,000, leading to&#xD;
      more than 9,000 amputations and about 7,000 deaths.&#xD;
&#xD;
      Snake bites are recognized by many authors as a neglected disease, whose incidence is&#xD;
      underestimated or even unknown in several countries of sub-Saharan Africa. Few data are&#xD;
      currently available on the morbidity, mortality and economic impact of snake bites.&#xD;
&#xD;
      In Cameroon and particularly in the northern part of the country, where the density of snakes&#xD;
      is high, a few studies have been carried out. In 2002, the annual incidence of envenomings&#xD;
      was estimated at 200/100 000 inhabitants, of which 85% was due to Echis ocellatus, and the&#xD;
      lethality was 23.9% in some centers. The Ministry of Public Health introduced snake bites in&#xD;
      2015 as a priority health problem in the list of diseases being monitored. Thus, a national&#xD;
      epidemiological surveillance system, with a weekly count of snake bites, has been&#xD;
      implemented. In the first year, the incidence of annual snake bites was 11.4/100,000&#xD;
      inhabitants, representing more than 2,500 bites per year, including 43 deaths and a case&#xD;
      fatality rate of up to 6% in some areas. The northern region (Adamaoua, North and Far North&#xD;
      regions) (savanna and mixed zone) accounts for 40% of the country's burden and 77% of the&#xD;
      deadly burden, while the forest zone accounts for 32% of the burden Morbid disease and 16% of&#xD;
      the fatal burden (ministerial source). The monitoring is based on paper registers for bite&#xD;
      reporting, supplemented by the sending of pharmacovigilance data by text messages, but this&#xD;
      is very little used in current practice. The data collection system in Cameroon could&#xD;
      therefore be improved in terms of both completeness and speed of centralizing data.&#xD;
&#xD;
      These estimates are likely to be well below the reality given the non-exhaustive nature of&#xD;
      the data collection and the frequent use of traditional practitioners without referral in a&#xD;
      hospital structure.&#xD;
&#xD;
      In recent years, FAV-Afrique® produced by Sanofi-Pasteur was the treatment of reference for&#xD;
      venomous snake bites in West and Central Africa. It was the most evaluated and the most&#xD;
      effective, reducing by a factor 5 to 10 the mortality. This anti-venom serum was&#xD;
      polyspecific, containing an antivenom against ten species of snakes: Naja melanoleuca,&#xD;
      nigricollis &amp; haje; Dendroaspis polylepis, viridis &amp; jamesoni, Bitis gabonica &amp; arietans;&#xD;
      Echis leucogaster &amp; ocellatus.&#xD;
&#xD;
      However, Sanofi-Pasteur stopped production (last batch produced in January 2014 and expired&#xD;
      in June 2016), making it necessary to use other snake antivenoms. Since the end of 2015, two&#xD;
      new antivenoms are available in Cameroon where they are granted a provisional marketing&#xD;
      authorization. Few clinical trials have evaluated the antivenoms currently available in&#xD;
      Africa.&#xD;
&#xD;
      Some clinical efficacy and safety data have been published for Inoserp Pan-Africa®. However,&#xD;
      the number of subjects was limited and assessment was limited to the period of&#xD;
      hospitalization.&#xD;
&#xD;
      The lack of sufficient data on incidence and mortality associated with snake bites, the&#xD;
      current weakness of the epidemiological data collection system and the presence on the market&#xD;
      of antivenoms that are very little evaluated in terms of tolerance, effectiveness make action&#xD;
      necessary.&#xD;
&#xD;
      The main objective of the study is therefore to assess the tolerance and the efficacy of the&#xD;
      antivenom Inoserp Pan-Africa® from Inosan laboratory currently available in Cameroon.This&#xD;
      study will be conducted under routine conditions in order to avoid bias in the results&#xD;
      through the implementation of dedicated logistics which would not be representative of the&#xD;
      usual conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 17, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Short term tolerance of the antivenom serum Inoserp Pan-Africa®</measure>
    <time_frame>30 months</time_frame>
    <description>The short-term tolerance of the antivenom serum Inoserp Pan-Africa® will be assessed by the monitoring of the clinical signs occurence less than 2 hours post-injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Short term efficacy of the antivenom serum Inoserp Pan-Africa®</measure>
    <time_frame>30 months</time_frame>
    <description>The short-term efficacy of the antivenom serum Inoserp Pan-Africa® will be assessed by the clinical evaluation when the patient arrives at the hospital and then regularly until 48 hours post-injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medium term tolerance of the antivenom serum Inoserp Pan-Africa®</measure>
    <time_frame>30 months</time_frame>
    <description>The medium term tolerance of the antivenom serum Inoserp Pan-Africa® will be assessed by the monitoring of the clinical signs occurence more than 72 hours post-injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medium term efficacy of the antivenom serum Inoserp Pan-Africa®</measure>
    <time_frame>30 months</time_frame>
    <description>The medium term efficacy of the antivenom serum Inoserp Pan-Africa® will be assessed by the vital status at 15 days of any patient who received at least one dose of the antivenom serum and by the reported consequences 15 days after the first dose administration of the antivenom serum</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">470</enrollment>
  <condition>Snake Bites</condition>
  <condition>Antivenins</condition>
  <condition>Snake Venoms</condition>
  <arm_group>
    <arm_group_label>Patients bitten by a snake</arm_group_label>
    <description>Any patient over 5 years old going to a participating center for curative care following a snake bite.&#xD;
Participation to the study does not change usual follow-up of patients. Antivenom serum Inoserp Pan-Africa® injection will be decided according to the clinical evaluation of the patient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antivenom serum Inoserp Pan-Africa® injection</intervention_name>
    <description>Participation to the study does not change usual follow-up of patients. All medical procedures will be performed and products will be used in a routine manner. Antivenom serum Inoserp Pan-Africa® injection will be decided according to the clinical evaluation of the patient.</description>
    <arm_group_label>Patients bitten by a snake</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Any patient over 5 years old (inclusive) visiting at a participating center for curative&#xD;
        care following a snake bite, with or without confirmed envenoming, will be proposed to&#xD;
        participate in the study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any patient over 5 years old (inclusive) visiting at a participating center for a&#xD;
             snake bite with or without confirmed envenoming&#xD;
&#xD;
          -  Informed consent to research&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient refusal&#xD;
&#xD;
          -  Under 5 year-old&#xD;
&#xD;
          -  Antivenom serum administration before the arrival in the participating center&#xD;
&#xD;
          -  History of severe allergic reactions to antivenom serum&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armand Nkwescheu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cameroon Society of Epidemiology, Cameroon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yap Boum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Médecins Sans Frontière</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabien Taïeb, MD</last_name>
    <phone>1 44 38 93 10</phone>
    <phone_ext>+33</phone_ext>
    <email>fabien.taieb@pasteur.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yoann Madec</last_name>
    <phone>1 40 61 38 28</phone>
    <phone_ext>+33</phone_ext>
    <email>yoann.madec@pasteur.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital de District d'Akonolinga</name>
      <address>
        <city>Akonolinga</city>
        <country>Cameroon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larissa MVOGO, MD</last_name>
      <phone>676 92 32 23</phone>
      <email>larissamvogo@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital régional de Buea</name>
      <address>
        <city>Buea</city>
        <country>Cameroon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MOKAKE, MD</last_name>
      <phone>676413408</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de District de Guider</name>
      <address>
        <city>Guider</city>
        <country>Cameroon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>OUSMANA, MD</last_name>
      <phone>699358210</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de District de Kolofata</name>
      <address>
        <city>Kolofata</city>
        <country>Cameroon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kouli Guidang</last_name>
      <phone>695 22 37 44</phone>
      <email>kouliguidang@yahoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Régional de Limbe</name>
      <address>
        <city>Limbe</city>
        <country>Cameroon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kinge Njie THOMPSON</last_name>
      <phone>677623606</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de District de Mora</name>
      <address>
        <city>Mora</city>
        <country>Cameroon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume GAYMA, MD</last_name>
      <phone>694263357</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Norvégien de N'Gaoundéré</name>
      <address>
        <city>N'Gaoundéré</city>
        <country>Cameroon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans NOTAYA, MD</last_name>
      <phone>653725152</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Régional de N'Gaoundéré</name>
      <address>
        <city>N'Gaoundéré</city>
        <country>Cameroon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BALDAGAI, MD</last_name>
      <phone>697968616</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Malte de Njombe</name>
      <address>
        <city>Njombé</city>
        <country>Cameroon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>METOMO, MD</last_name>
      <phone>678267893</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de District de Poli</name>
      <address>
        <city>Poli</city>
        <country>Cameroon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moustafa HAMDJA, MD</last_name>
      <phone>698149374</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de District de Sa'a</name>
      <address>
        <city>Sa'a</city>
        <country>Cameroon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>FOE, MD</last_name>
      <phone>697358979</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de District de Tokombere</name>
      <address>
        <city>Tokombere</city>
        <country>Cameroon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre AMTA, MD</last_name>
      <phone>237 74928040</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre des Urgences de Yaounde (CURY)</name>
      <address>
        <city>Yaoundé</city>
        <country>Cameroon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard MBARGA METOGO, MD</last_name>
      <phone>699 55 35 22</phone>
      <email>bernardmetogo@yahoo.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>Cameroon</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 29, 2017</study_first_submitted>
  <study_first_submitted_qc>October 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2017</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Snake bites</keyword>
  <keyword>Antivenom serum</keyword>
  <keyword>Snake venoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Snake Bites</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antivenins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

